V8 Peptides — Engineered Performance
Research Library
What Is Reta? Retatrutide (LY3437943) Explained for Researchers
RetatrutideGuideExplainer

What Is Reta? Retatrutide (LY3437943) Explained for Researchers

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

"Reta" is shorthand for retatrutide (LY3437943), an investigational lipidated 39-residue peptide that activates the glucagon, GIP and GLP-1 receptors. It was developed by Eli Lilly, and its discovery paper describes balanced glucagon-receptor and GLP-1-receptor activity with more GIP-receptor activity in vitro. It is not a company or a different drug from retatrutide. V8 supplies it for laboratory research only, with an Accumark Labs HPLC report on the COA page.

Reta (retatrutide) key facts

ItemDetail
What "reta" meansShorthand for retatrutide; also written LY3437943, its Eli Lilly development code
ClassInvestigational, once-weekly, lipidated 39-residue peptide (Mateescu 2026)
Receptor targetsGlucagon receptor (GCGR), GIP receptor (GIPR) and GLP-1 receptor (GLP-1R): a triple agonist (Coskun 2022)
In vitro profileBalanced GCGR and GLP-1R activity with more GIPR activity (Coskun 2022)
OriginatorEli Lilly and Company (author affiliation, Coskun 2022)
StatusDescribed as investigational in a 2026 review (Mateescu 2026)
Not to be confused withSemaglutide (GLP-1 receptor analog) and tirzepatide (GIP/GLP-1); see the comparison below
V8 lab reportRetatrutide 10 mg lot, Accumark Labs, published 10/18/2026: HPLC purity 99.96% (spec above 98.0%), measured quantity 9.944 mg against a 10.0 mg label, endotoxin below the quantitation limit (spec 5 EU/mL or less), rapid PCR sterility screen not detected
Supplied asLyophilized powder, research use only: Retatrutide research peptide

Last reviewed November 21, 2026 by the V8 Peptides Research Team. Each reference links to its PubMed or publisher record. For laboratory research use only.

Why people search "reta"

"Reta" is simply the short form of retatrutide. Queries such as "reta peptide", "reta drug", "what is reta" and "retapeptide" all point to the same compound, which also appears in papers under its development code LY3437943. "Reta" is not a company or a separate molecule. A listing that uses the word still has to be checked like any other: the name on a label cannot tell you what is in the vial, only a lab report for that product can.

Where retatrutide comes from

The discovery paper from Eli Lilly (Coskun et al., 2022) describes LY3437943 as a novel triple agonist peptide at the glucagon, GIP and GLP-1 receptors. In vitro it showed balanced glucagon-receptor and GLP-1-receptor activity with more GIP-receptor activity. In obese mice, the paper reports that body-weight loss was augmented when glucagon-receptor-mediated energy expenditure was added to the GIP- and GLP-1-receptor-driven reduction in calorie intake, and a phase 1 single-dose study supported once-weekly pharmacokinetics. A 2026 critical review (Mateescu et al.) describes the molecule as a lipidated 39-residue peptide, covers its molecular engineering and pharmaceutical development, and still calls it investigational.

Reta compared with related incretin peptides

CompoundReceptors engagedSource
Retatrutide (reta)GCGR + GIPR + GLP-1RCoskun 2022; Mateescu 2026
SemaglutideGLP-1R; a GLP-1 analogue with Aib at position 8 and Arg at position 34, derivatized at Lys26Lau 2015; see semaglutide vs Ozempic and Wegovy
TirzepatideGIPR + GLP-1R (dual agonist)Compared in retatrutide vs tirzepatide

The practical point for a laboratory is that the three molecules are not interchangeable reagents: receptor panel, chain length and lipid modification all differ, so assay results cannot be carried from one to the other. Our four-way comparison sets them side by side, and the retatrutide research overview covers the receptor biology in more depth.

What affects the price of research-grade reta

Price differences between sellers usually come from things you can check: whether a lot has an independent HPLC report, whether quantity is measured against the label, whether endotoxin and sterility screens were run, how the powder is packed, and whether the seller replaces damaged vials. A very low price with no report for that product is a reason to ask questions, not a bargain. The Retatrutide 10 mg report we publish shows the lines to look for: purity 99.96%, measured quantity 9.944 mg against a 10.0 mg label, endotoxin below the quantitation limit and no microbial DNA detected in the PCR screen. Reports for other lots and sizes are on the COA page.

Storage and handling at a glance

Research peptides of this type are supplied as lyophilized powder, the most stable form. Keep the sealed vial cold, dry and away from light and heat, and avoid repeated warming and cooling. Once reconstituted for an assay, treat the solution as short-lived and write down the date. Details are in retatrutide storage and stability and retatrutide reconstitution and handling; the reconstitution calculator converts vial mass and diluent volume to mg/mL. If you are choosing a seller, where to buy retatrutide and choosing a peptide supplier list the documents to ask for. V8 ships within the United States only, from Florida.

Reading a retatrutide listing

A retatrutide listing should answer a short list of questions before you add anything to a cart. Does it name the product size the report covers? Does the report come from a named independent laboratory and show a purity percentage, an identity result and measured quantity? Is there an endotoxin result if you plan cell work? Is the shipping geography clear, and is there a remedy for a damaged package? On the V8 report, for example, the 10 mg lot shows purity of 99.96% and 9.944 mg measured against a 10.0 mg label, so the quantity is 99.4% of the label. Listings that quote a purity figure but no laboratory, or a report for a different compound, fail the first test.

Why a 39-residue lipidated peptide needs careful verification

The 2026 review of retatrutide's pharmaceutical development lists scalable synthesis, impurity and potency control, formulation stability and reliable delivery among the priorities for this class (Mateescu et al.). The same issues matter on a research bench. A long chain carrying a fatty-acid side chain has more places for deletions, truncations and side-chain variants to arise during manufacture, and more ways to degrade in storage, than a five- or six-residue peptide. That is why an HPLC percentage and an identity result come together on one report, why quantity is measured, and why a seller who shows none of them cannot tell you what is in the vial.

Frequently asked questions

What is reta?

Reta is the common short name for retatrutide (development code LY3437943), a lipidated 39-residue investigational peptide that is an agonist at the glucagon, GIP and GLP-1 receptors.

What does reta peptide mean? Is "reta" the same as retatrutide?

Yes. "Reta" is only an abbreviation of retatrutide. It is not a separate drug, brand or company.

Who developed retatrutide (LY3437943)?

Eli Lilly and Company. The discovery paper by Coskun et al. (2022) in Cell Metabolism is from Lilly authors.

How is reta different from semaglutide and tirzepatide?

Semaglutide acts on the GLP-1 receptor, tirzepatide on the GIP and GLP-1 receptors, and retatrutide on the glucagon, GIP and GLP-1 receptors, so the three have different receptor panels and structures.

Why do prices for research reta vary so much?

Differences usually reflect whether a lot has an independent HPLC report, whether quantity is measured, endotoxin and sterility screening, packaging and the seller's replacement policy. A low price without a report for that product is a flag.

What should a retatrutide COA show?

The testing lab and date, an HPLC purity percentage, an identity result, measured quantity against the labelled amount, and ideally endotoxin and sterility results. V8's published 10 mg report shows purity 99.96% and 9.944 mg measured against a 10.0 mg label.

How is lyophilized reta stored?

Sealed, cold, dry and protected from light, with temperature cycling avoided. Reconstituted solutions are short-lived and should be dated.

Does V8 Peptides publish a lab report for retatrutide?

Yes. Reports from Accumark Labs for retatrutide lots are on the COA page. Check the list there for the size you are looking at.

Is this page advice for use in people?

No. V8 sells retatrutide for laboratory research only. The page describes published research and makes no claims about people or animals.

More from our research library: how to read a COA, Understanding HPLC purity, calculator guide.

All V8 Peptides products are sold for laboratory research use only. They are not drugs, foods, or cosmetics and are not intended for human or animal consumption. This article describes published research and makes no claims about use in people or animals.

References

  1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34:1234-1247.e9. PubMed 35985340 · doi:10.1016/j.cmet.2022.07.013
  2. Mateescu DM, Capraru ID, Enache B, et al. Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence. Pharmaceutics. 2026;18. PubMed 42942810 · doi:10.3390/pharmaceutics18101277
  3. Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58:7370-80. PubMed 26308095 · doi:10.1021/acs.jmedchem.5b00726

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.